Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
These recommendations will be subject to change upon formal regulatory approval and the publication of licensed prescribing guidance
Studies have shown Lillys dual GIP and GLP-1 receptor agonist has advantages, including greater weight loss, over Novos single-acting GLP-1 drug
Some key reasons active individuals consider GLP-1 therapy include: Reduced cravings and mindless snacking Improved consistency with nutrition plans Enhanced fat loss without extreme dieting Support for long-term weight management With professional supervision, GLP-1 for fitness enthusiasts can complement a structured training routine instead of working against it
Consider a typical case: a 45-year-old male starting at 270 pounds with hypertension, prediabetes, elevated cholesterol, and fatty liver disease
Peer review Peer review information Nature Chemistry thanks Daniel Reker and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
doi: 10.1056/NEJMoa1901118 67 ClinicalTrials.gov NCT03819153
